Venetoclax with Induction & Consolidation
A Phase II Randomized Clinical Trial of Venetoclax Combined With FLAG IDA Induction and Consolidation Compared to Standard of Care for Newly Diagnosed Patients With Acute Myeloid Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 102 patients (estimated)
- Sponsors
- Oregon Health and Science University
- Tags
- BCL-2 Inhibitor, Pre-Allogeneic Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2190
- NCT Identifier
- NCT07228273
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.